Alnylam Pharmaceuticals Careers in Cambridge, MA

We are developing new technologies and an entirely new class of innovative medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic and acute hepatic infectious diseases. Alnylam was founded in 2002 based on a Nobel Prize winning breakthrough in biology – the discovery of RNA interference and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments. Because patients shouldn’t have to wait for hope. Alnylam is a global and diverse company of more than 700 people with 7 programs in clinical development, including 4 late-stage programs.